Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Mol Pharm. 2011 Feb 15;8(2):621–628. doi: 10.1021/mp100446t

Figure 3.

Figure 3

(A) Representative decay-corrected whole-body coronal microPET images of mice bearing MDA-MB-435 breast cancer at 1.5 h after intravenous injection of 18F-FLT (1.85 MBq/mouse) on days 0, 1, 3, 7 and 14 after the treatment was initiated. The tumors are indicated by arrows. Decreased uptake of 18F-FLT was observed on day 1 and day 3 but resumed to baseline level on day 7. Upper panel: control; Lower panel: VEGF121/rGel treatment. (B) Quantitative microPET region of interest analysis of tumor uptake for 18F-FLT. (** p < 0.01)